Rocuronium B. Braun Solution for Injection/Infusion

Rocuronium B. Braun Solution for Injection/Infusion

rocuronium bromide

Manufacturer:

B. Braun

Distributor:

DKSH
/
Four Star
Concise Prescribing Info
Contents
Rocuronium Br
Indications/Uses
Adjunct to general anaesth to facilitate tracheal intubation during routine sequence induction & to provide skeletal muscle relaxation during surgery in adult & paed patients (from term neonates to adolescents, 0-<18 yr). Facilitates tracheal intubation during rapid sequence induction & for short-term use as adjunct in ICU to facilitate intubation & mechanical ventilation in adults.
Dosage/Direction for Use
IV Individualised dosage. Tracheal intubation in surgery &/or ICU Adult Standard intubation dose during routine anaesth: 0.6 mg/kg. Dose during rapid sequence induction of anaesth: 1 mg/kg. Maintenance: 0.15 mg/kg. In case of long-term inhalational anaesth, reduce to 0.075-0.1 mg/kg. Continuous infusion Loading dose: 0.6 mg/kg, then start administration by infusion when neuromuscular block starts to recover. Infusion rate under IV anaesth: 0.3-0.6 mg/kg/hr. Infusion rate under inhalational anaesth: 0.3-0.4 mg/kg/hr. Paed patient Same intubation dose w/ adult during routine anaesth & maintenance dose. For continuous infusion, higher infusion rates might be necessary. Elderly patient & patient w/ hepatic &/or biliary tract disease &/or renal failure Standard intubation dose during routine anaesth & dose during rapid sequence induction of anaesth: 0.6 mg/kg. Maintenance: 0.075-0.1 mg/kg. Infusion rate: 0.3-0.4 mg/kg/hr. Pregnant patient undergoing Caesarean section 0.6 mg/kg. Overwt & obese patient Doses should be reduced taking into account the lean body mass.
Contraindications
Special Precautions
Anaphylactic reactions can occur after administration. Reports of allergic cross-reactivity to neuromuscular blocking agents. Ventilatory support is mandatory until adequate spontaneous respiration is restored. Reports of residual curarization. Dose levels >0.9 mg/kg may increase heart rate. Risk of prolonged paralysis &/or skeletal muscle weakness following long-term use in ICU. Strongly recommended to monitor neuromuscular transmission throughout use. Reports of myopathy after long-term co-administration w/ corticosteroids. If suxamethonium is used for intubation, delay rocuronium administration until patient recovers from suxamethonium-induced neuromuscular block. Conditions associated w/ prolonged circulation time eg, CV diseases, advanced age & oedematous state resulting in an increased vol of distribution; hypothermic conditions in surgery; hypokalaemia, hypermagnesaemia, hypocalcaemia, hypoproteinaemia, dehydration, acidosis, hypercapnia, cachexia. Patients w/ neuromuscular disease or after poliomyelitis; w/ myasthenia gravis or myasthenic (Eaton-Lambert) syndrome; obese patients; patients w/ burns. Not recommended to use potentially dangerous machinery or to drive during the 1st 24 hr after full recovery from neuromuscular blocking action. Patients w/ clinically significant hepatic &/or biliary diseases &/or renal failure. Pregnancy & lactation. Patients receiving Mg salts for toxemia of pregnancy. Not recommended for facilitation of tracheal intubation during rapid sequence induction in paed patients.
Adverse Reactions
Pain &/or local reactions around inj site, changes in vital functions, prolonged neuromuscular block.
Drug Interactions
Increased effect w/ halogenated volatile anaesth; w/ high doses of thiopental, methohexital, ketamine, fentanyl, gammahydroxybutyrate, etomidate, propofol; after intubation w/ or prior administration of suxamethonium; long-term concomitant use w/ corticosteroids in ICU; antibiotics eg, aminoglycosides, lincosamides (lincomycin & clindamycin), polypeptide antibiotics, acylamino-penicillin antibiotics, tetracyclines, high doses of metronidazole; diuretics, quinidine & its isomer quinine, protamine, adrenergic blocking agents, Mg salts, Ca channel blocking agents, lithium salts & local anaesth (lidocaine IV, bupivacaine epidural) & acute administration of phenytoin or β-blocking agents. Reports of recurarization after post-op administration of aminoglycoside, lincosamide, polypeptide & acylamino-penicillin antibiotics, quinidine, quinine & Mg salts. Decreased effect w/ neostigmine, edrophonium, pyridostigmine, aminopyridine derivatives; prior chronic administration of phenytoin or carbamazepine; PIs. Attenuated/potentiated neuromuscular block w/ other non-depolarising neuromuscular blocking agents. Faster onset of lidocaine effect.
ATC Classification
M03AC09 - rocuronium bromide ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.
Presentation/Packing
Form
Rocuronium B. Braun Solution for Injection/Infusion 50 mg/5 mL
Packing/Price
5 mL x 20 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in